Great West Life Assurance Co. Can Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Great West Life Assurance Co. Can increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,300 shares of the medical research company’s stock after buying an additional 97 shares during the period. Great West Life Assurance Co. Can owned about 0.09% of IQVIA worth $41,012,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in IQV. Credit Suisse AG boosted its position in shares of IQVIA by 8,868.0% in the 1st quarter. Credit Suisse AG now owns 850,346 shares of the medical research company’s stock worth $164,235,000 after buying an additional 840,864 shares in the last quarter. BlackRock Inc. boosted its position in shares of IQVIA by 5.4% in the 2nd quarter. BlackRock Inc. now owns 15,579,850 shares of the medical research company’s stock worth $3,775,310,000 after buying an additional 797,361 shares in the last quarter. FIL Ltd lifted its holdings in IQVIA by 190.1% in the 1st quarter. FIL Ltd now owns 919,341 shares of the medical research company’s stock valued at $177,562,000 after purchasing an additional 602,391 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in IQVIA by 88.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 981,645 shares of the medical research company’s stock valued at $189,594,000 after purchasing an additional 459,394 shares in the last quarter. Finally, Primecap Management Co. CA lifted its holdings in IQVIA by 98.0% in the 1st quarter. Primecap Management Co. CA now owns 610,847 shares of the medical research company’s stock valued at $117,979,000 after purchasing an additional 302,264 shares in the last quarter. Institutional investors and hedge funds own 87.01% of the company’s stock.

IQV opened at $261.61 on Friday. The firm has a 50 day moving average price of $254.11 and a 200 day moving average price of $235.41. The company has a market cap of $50.13 billion, a PE ratio of 83.85, a price-to-earnings-growth ratio of 2.43 and a beta of 1.42. IQVIA Holdings Inc. has a 1 year low of $146.03 and a 1 year high of $265.34. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.05 and a current ratio of 1.05.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 27th. The medical research company reported $2.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.07 by $0.06. The firm had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.27 billion. IQVIA had a net margin of 4.69% and a return on equity of 23.95%. The company’s revenue was up 36.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.18 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 8.25 earnings per share for the current year.

A number of research analysts have issued reports on the stock. Mizuho upped their target price on shares of IQVIA from $250.00 to $270.00 and gave the company a “buy” rating in a report on Wednesday, July 28th. Deutsche Bank Aktiengesellschaft upped their target price on shares of IQVIA from $244.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, July 28th. Robert W. Baird upped their target price on shares of IQVIA from $273.00 to $285.00 and gave the company an “outperform” rating in a report on Wednesday, July 28th. Credit Suisse Group upped their target price on shares of IQVIA from $242.00 to $265.00 and gave the company an “outperform” rating in a report on Tuesday, July 20th. Finally, Morgan Stanley upped their price objective on shares of IQVIA from $260.00 to $280.00 and gave the company an “overweight” rating in a research note on Wednesday, July 28th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, IQVIA has a consensus rating of “Buy” and a consensus price target of $262.33.

About IQVIA

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment provides mission critical information, technology solutions and real world solutions and services to the firm’s life science clients.

Read More: Terms to Better Understand Call Options

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.